Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.
Lee, K.L., Ambler, C.M., Anderson, D.R., Boscoe, B.P., Bree, A.G., Brodfuehrer, J.I., Chang, J.S., Choi, C., Chung, S., Curran, K.J., Day, J.E., Dehnhardt, C.M., Dower, K., Drozda, S.E., Frisbie, R.K., Gavrin, L.K., Goldberg, J.A., Han, S., Hegen, M., Hepworth, D., Hope, H.R., Kamtekar, S., Kilty, I.C., Lee, A., Lin, L.L., Lovering, F.E., Lowe, M.D., Mathias, J.P., Morgan, H.M., Murphy, E.A., Papaioannou, N., Patny, A., Pierce, B.S., Rao, V.R., Saiah, E., Samardjiev, I.J., Samas, B.M., Shen, M.W.H., Shin, J.H., Soutter, H.H., Strohbach, J.W., Symanowicz, P.T., Thomason, J.R., Trzupek, J.D., Vargas, R., Vincent, F., Yan, J., Zapf, C.W., Wright, S.W.
J. Med. Chem.